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DObjective: Compared with reoperative aortic valve replacement for nonendocarditic causes, the contemporary
risk and long-term outcomes of reoperation for aortic prosthetic valve endocarditis are ill-defined.
Methods: Between December 1994 and April 2008, 313 patients underwent reoperative aortic valve replace-
ment, of whom 152 (48.6%) had prosthetic valve endocarditis. Mean follow-up was 6.5  0.4 years and
97.4% complete.
Results: Patients with prosthetic valve endocarditis were older with a higher risk profile. The overall hospital
mortality was 15.3% (n ¼ 48) (prosthetic valve endocarditis vs nonendocarditis: 24.3%, n ¼ 37, vs 6.8%,
n¼ 11; P<.001). Independent predictors of perioperativemortality for prosthetic valve endocarditis were sepsis
(odds ratio [OR], 6.5; 95% confidence interval [CI], 2.0–21.0; P<.01), ejection fraction less than 30% (OR, 5.8;
95% CI, 1.3–25.0; P¼ .02), concomitant coronary artery bypass grafting (OR, 3.3; 95% CI, 1.1–9.8; P¼ .03),
and aortic root abscess (OR, 2.7; 95% CI, 1.2–6.4; P ¼ .02), and for the nonendocarditis group were concom-
itant coronary artery bypass grafting (OR, 8.1; 95% CI, 2.0–33.0; P<.01), and mitral valve surgery (OR, 4.8;
95% CI, 1.3–17.9; P ¼ .02). The 1-, 3-, 5-, and 10-year survivals for patients with and without prosthetic valve
endocarditis were 52%  4% versus 82%  3%, 43%  5% versus 73%  4%, 37%  5% versus 63% 
5%, and 31%  7% versus 56%  8%, respectively (log rank<0.001). Predictors of long-term mortality in
prosthetic valve endocarditis were sepsis (OR, 3.1; 95% CI, 1.5–4.5; P<.01) and unstable preoperative status
(OR, 1.8; 95%CI, 1.2–3.5; P¼ .04), whereas in nonendocarditis patients the only predictor was NewYork Heart
Association class IV (OR, 2.5; 95% CI, 2.8–7.4; P<.01). Five-year actuarial freedom from endocarditis was
80%  0.3% versus 95%  0.6% (prosthetic valve endocarditis cersus nonendocarditis; P ¼ .002).
Conclusions: Despite contemporary therapy, reoperation for aortic prosthetic valve endocarditis is still associ-
ated with relatively high perioperative mortality and limited long-term survival. (J Thorac Cardiovasc Surg
2011;142:99-105)Aortic valve replacement (AVR) is a frequently performed
operation with more than 20,000 isolated procedures and
16,000 combined with coronary artery bypass grafting
(CABG) reported to the Society of Thoracic Surgeons
database in 2008 (http://www.sts.org/documents/pdf/ndb/
2ndHarvestExecutiveSummary_2009.pdf). The operative
risks for isolated AVR and AVRþCABG have now fallen
below 3.2% and 5.0%, respectively, according to the
database. Serious complications of prosthetic valves occur
in 2% to 3% per patient-year, with prosthetic valve endo-
carditis (PVE) occurring in 0.98% per patient-year.1 Thee Department of Cardiac Surgery, Heart Center, University of Leipzig, Leip-
ermany.
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The Journal of Thoracic and Ccumulative incidence at 5 years is 3% and at 10 years,
5%.2 PVE now represents about one fifth of all cases of
infective endocarditis, occurring for example in 26% of
cases in the Euro Heart Survey and in 556 (20.1%) of
2670 patients with definite endocarditis in the International
Collaboration on Endocarditis–Prospective Cohort Study.3
Reoperative surgery is needed in approximately 42% to
49% of patients with PVE, but the contemporary risk and
long-term outcomes of this, particularly with periannular in-
volvement, remain ill-defined. Much of our current under-
standing is based on studies limited by small sample
size and retrospective design and many antedate the routine
use of echocardiography and the contemporary and vali-
dated Duke diagnostic criteria.3,4 Reported mortalities of
surgical intervention have ranged from 13% to 80%, and
better identification of high-risk subgroups of patients is re-
quired. This has implications for the assessment of an indi-
vidual patient’s suitability for reoperative surgery and
conceivably also the choice of prosthetic valve substitute.
The objectives of this study were to (1) prospectively de-
scribe the clinical characteristics, outcome, and survival of
patients undergoing reoperation for aortic PVE, (2) compareardiovascular Surgery c Volume 142, Number 1 99
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PVE ¼ prosthetic valve endocarditis
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Dthis to a reference group of reoperativeAVR for nonendocar-
ditic causes, and (3) determine prognostic factors for both
early mortality and long-term survival in both groups.
PATIENTS AND METHODS
Patients
This study was reviewed and approved by the Institutional Review
Board at Herzzentrum, Universita¨t Leipzig (Leipzig, Germany). All pa-
tients undergoing reoperative AVR over a 14-year period between Decem-
ber 1994 and April 2008 were selected. Patients undergoing concomitant
coronary, valvular, or aortic surgery were included. Patients were classified
according to the presence of PVE diagnosed according to the modified
Duke criteria.4 For patients with PVE, the surgical tenet of radical debride-
ment of all infected tissue, drainage and exclusion of myocardial abscesses
from the bloodstream, and repair of annular defects was adhered to. The
choice of the best valvular substitute was left to the discretion of the sur-
geon. Data were prospectively collected from a computer registry main-
tained prospectively. Patients were followed up annually by postal
questionnaire and, when needed, by contacting the referring cardiologist
or family physician.
Definitions
In accordancewith Society of Thoracic Surgeons guidelines, early mor-
tality was defined as all-cause mortality at 30 days. Nonstructural dysfunc-
tion was defined as any abnormality not intrinsic to the valve itself that
resulted in stenosis or regurgitation of the operated valve or hemolysis,
such as pannus ingrowth or paravalvular leak. In contrast, structural valve
deteriorationwas dysfunction or deterioration involving the operated valve
related to an intrinsic abnormality, such as calcification or leaflet tears. Op-
erations were considered emergency if performed within 24 hours of hos-
pital admission for cardiovascular instability and urgent if performed
during the index hospital admission. Sepsis was defined as fever, leukocy-
tosis, positive blood culture, hemodynamic instability needing vasopres-
sors, or organ failure. Early endocarditis was defined as occurring within
1 year of the operation. Complications from PVE were defined as perian-
nular abscess, thromboembolic events, sepsis, or critical preoperative state.
Statistical Analysis
Continuous variables are expressed as mean  standard deviation and
compared using an unpaired Student t test or Kruskal–Wallis test; categor-
ical data are presented as proportions and compared using the c2 or Fisher’s
exact test. Univariate and multivariate logistic regression modeling with
backward stepwise elimination was performed separately for PVE and
non-PVE inasmuch as these 2 entities displayed profound pathophysiologic
and prognostic differences. The 23 factors listed in Appendix 1were used to
constructmodels of adverse outcomes and are expressed as odds ratios (OR)
and 95% confidence intervals (CI). For multiple comparisons, analysis of
variance was performed using a Bonferroni correction. Event-free survival
was calculated by Kaplan–Meier methods. Independent predictors of
long-term survival were determined using Cox proportional hazards100 The Journal of Thoracic and Cardiovascular Surganalysis. All statistical analyses were performed using SPSS 17.0 (SPSS
Inc, Chicago, Ill).RESULTS
This study included 313 patients undergoing reoperative
AVR, of whom 152 (48.6%) had PVE and 161 (51.4%) did
not. Patients with PVE had a higher risk profile, being older
with more urgent/emergency cases and a higher incidence
of preoperative neurologic dysfunction, thromboembolic
events, renal failure, diabetes, and congestive cardiac fail-
ure (Table 1). Sixty-four (42.1%) patients with PVE had
an aortic root abscess with the most common organism be-
ing Staphylococcus in 50%. Cerebral embolism occurred in
15 (9.9%) patients and renal or splenic emboli in 26
(17.1%) (indications not mutually exclusive). Endocarditis
was classified as active in all patients. In patients with early
PVE, the most common organisms were coagulase-negative
Staphylococcus and S aureus, whereas Streptococcus and
gram-negative infections were more common in late PVE
(Table 2). Patients with PVE were more likely to have
had either a xenograft or concomitant mitral valve operation
and less likely to have had a mechanical prosthesis at the
primary operation compared with patients without endocar-
ditis (Table 3).
The reasons for reoperation in patients with PVE were
periannular complications in 42.1% (n¼ 64), systemic em-
bolization in 27% (n¼ 41), prosthetic dysfunction leading to
cardiac failure in 19.1% (n¼ 29), persistent sepsis in 15.8%
(n¼ 24), and largemobile vegetation in 13.4% (n¼ 42). The
reasons for reoperation in those without endocarditis were
nonstructural dysfunction (n ¼ 62, 38.5%), structural dys-
function (n¼ 57, 35.4%), aortic root aneurysm or dissection
(n ¼ 30, 18.6%), and valve thrombosis (n ¼ 12, 7.5%).
The most common procedure performed for PVE was an
aortic root replacement (aortic root  concomitant proce-
dure vs AVR  concomitant procedure, 55.8% vs 43%;
P<.01). For nonendocarditic reoperations, AVR and root
replacement were performed with similar frequency
(46.4% vs 50.8%, respectively; P ¼ .1).
Concomitant Procedures
Concomitant mitral valve surgery was needed more fre-
quently in patients with PVE (38.8% vs 20.5%; P<.01;
PVE vs non-PVE), most commonly owing to either mitral
regurgitation (26% vs 13%;P¼ .005) ormitral endocarditis
(prosthetic mitral endocarditis 8.5% [n¼ 13] and nativemi-
tral endocarditis 9.5% [n¼ 14] vs 0%;P¼ .002).Only 27%
and 21% of these patients (PVEvs non-PVE) underwentmi-
tral valve repair; the majority of valves were replaced.
CABG was required in similar proportions in each group
(15.1% vs 12.3%; P ¼ .5; PVE vs non-PVE). The indica-
tion for aortic surgery was either ascending aortic or arch
aneurysm (8% vs 29%; P < .01) or aortic dissection
(1.3% vs 4.3%; P ¼ .1).ery c July 2011
TABLE 1. Demographic and preoperative clinical characteristics
PVE Non-PVE P
N 152 161
Age (y) 65.8  14.7 57.6  16.2 <.01
Female 31 (20) 45 (28) .1
Timing
Elective 20 (13.2) 93 (57.8) <.01
Urgent 65 (42.8) 50 (31.1) .03
Emergency 67 (44) 18 (11.3) <.01
Interval from primary
operation (y)
Mechanical 7.7  5.7 10.4  6.8 .01
Bioprosthetic 2.2  2.5 4.9  3.6 <.001
COPD 17 (11.2) 20 (12.4) .7
PVD 7 (4.6) 9 (5.6) .6
Neurologic dysfunction 41 (27.0) 15 (9.3) <.001
Serum creatinine>200 mmol/L 19 (12.5) 5 (3.1) .002
Diabetes mellitus 42 (27.6) 31 (19.3) .03
Ejection fraction
30%–50% 45 (29.6) 45 (28.0) .7
<30% 11 (7.2) 19 (11.8) .1
Pulmonary hypertension 19 (12.5) 19 (11.8) .8
CCF 29 (19.1) 8 (5.0) <.01
NYHA III–IV 89 (58.5) 64 (39.7) .001
Data shown are numbers of cases (%), unless otherwise indicated. CCF, Congestive
cardiac failure;COPD, chronic obstructive pulmonarydisease;NYHA,NewYorkHeart
Association; PVD, peripheral vascular disease; PVE, prosthetic valve endocarditis.
TABLE 3. Primary and reoperative surgical details
Primary Reoperation
PVE Non-PVE P PVE Non-PVE P
Valve substitute
Bioprosthesis 97 (63.8) 52 (32.3) <.001 131 (86.2) 152 (94.4) .07
Mechanical 51 (33.6) 83 (51.6) <.001 8 (5.3) 9 (5.6) .3
Homograft 3 (2.0) 7 (4.3) .2 13 (8.5) 0 <.001
Other* 1 (0.6) 19 (11.8) .02 0 0 1
Concomitant
Mitral valve 26 (17.1) 14 (8.7) .02 52 (34.2) 32 (19.9) .01
CABG 29 (19.1) 19 (11.8) .07 23 (15.1) 16 (9.9) .4
Asc aorta/arch 9 (5.9) 3 (1.9) .06 19 (12.5) 27 (16.7) .2
Data shownare numbers of cases (%).PVE,Prosthetic valve endocarditis;CABG, cor-
onary artery bypass grafting. *Other: Ross operation, aortic valve commisurotomy.
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In concordance with patients with PVE being an alto-
gether more complex and sicker group, they had longer op-
erative times and higher incidence of postoperative
complications (Table 4). Thirty-day mortality for the entire
cohort was 15.3% (n ¼ 48) and patients with PVE had
higher mortality than those without PVE (24.3%, n ¼ 37TABLE 2. Microbiological data for patients with PVE*
Organism Early (n ¼ 39) Late (n ¼ 67) P
Staphylococcus species 19 (49) 23 (34) .2
S aureus 7 20
Coagulase-negative 8 3
Other Staphylococcus 4 0
Streptococcus species 3 (8) 11 (16) .04
Strep pneumonia 1 0
Other Streptococcus 2 11
Enterococcus species 8 (21) 12 (18) .6
Enterococcus faecalis 5 6
Other enterococcus 3 6
Gram-negative 0 5 (7) .09
E coli 0 3
Pseudomonas 0 1
Proteus 0 1
Candida 3 (8) 3 (4) .4
Other 0 3 (4) .1
Culture negative 6 (15) 10 (15) 1
Data shown are numbers of cases (%), unless otherwise indicated. PVE, Prosthetic
valve endocarditis. *Data are available for 106 patients.
The Journal of Thoracic and Cavs 6.8%, n ¼ 11; P< .001). Patients with complicated
PVE had higher mortality than those without complications
(30.9%, n ¼ 30 vs 12.7%, n ¼ 7; P ¼ .01). This difference
was greater when just restricted to those with periannular
abscesses (40.6%, n ¼ 26 vs 12.5%, n ¼ 11; P< .001).
The mortality of patients with uncomplicated PVE was
not significantly different from that of the non-PVE group
although it was nearly double, suggesting that a type II error
may have occurred (12.7%, n¼ 7 vs 6.8%, n¼ 11; P¼ .1;
respectively). In patients with PVE, both Staphylococcal in-
fection (23.8%, n ¼ 10 vs 15.6%, n ¼ 10, Staph vs non-
Staph infection; P ¼ .3) and early endocarditis (23.5%;
n ¼ 12 vs 24.8%, n ¼ 25 early vs late endocarditis;
P ¼ .5) did not influence mortality.
Univariate analysis of risk factors (Appendix 1) for mor-
tality in the PVE group identified sepsis (OR, 10.1; 95%
CI, 3.6–28.0; P< .01), left ventricular ejection fraction
less than 30% (OR, 4.6; 95% CI, 1.3–16.9; P<.01), con-
comitant procedures (CABG: OR, 3.1; 95% CI, 1.2–7.7;
P ¼ .01; mitral valve surgery: OR, 2.6; 95% CI, 1.2–5.4;TABLE 4. Intraoperative and postoperative results
PVE Non-PVE P
Operative time (min) 310.1  121.1 254.7  98.8 .009
CPB time (min) 204.4  105.6 159.8  81.9 .006
Crossclamp time (min) 126.9  54.6 95.8  41.4 <.001
Reoperation for bleeding 29 (19.1) 19 (11.8) .7
Low cardiac output 45 (29.6) 22 (13.7) .001
IABP 32 (21.1) 10 (6.2) <.001
Pneumonia 28 (18.4) 23 (14.3) .3
Stroke 10 (6.6) 5 (3.1) .1
Renal failure 38 (25) 22 (13.7) .01
Gastrointestinal ischemia 17 (11.2) 5 (3.1) .005
Pacemaker implantation 39 (25.7) 38 (23.6) .6
Early endocarditis 4 (2.6) 0 (0) .04
Hospital stay (d) 20  21 16  11 .011
Thirty-day mortality 37 (24.3) 11 (6.8) <.001
Data shown are mean  standard deviation, or number of cases (%) where appropri-
ate. CPB, Cardiopulmonary bypass, IABP, intra-aortic balloon pump; PVE, prosthetic
valve endocarditis.
rdiovascular Surgery c Volume 142, Number 1 101
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DP ¼ .02), aortic root abscess (OR, 2.7; 95% CI, 1.1–6.4;
P ¼ .02), diabetes mellitus (OR, 2.3; 95% CI, 1.0–4.8;
P ¼ .04), and preoperative New York Heart Association
(NYHA) class IV (OR, 2.2; 95% CI, 1.1–4.7; P ¼ .01).
However, by multivariate analysis, only sepsis (OR, 6.5;
95%CI, 2.0–21.0; P<.01), left ventricular ejection fraction
less than 30% (OR, 5.8; 95% CI, 1.3–25.0; P ¼ .02), con-
comitant CABG (OR, 3.3; 95% CI, 1.1–9.8; P ¼ .03), and
aortic root abscess (OR, 2.7; 95% CI, 1.2–6.4; P ¼ .02)
were independent predictors of mortality.
Postoperative causes of death in patients with PVE were
low cardiac output with multiorgan dysfunction (n ¼ 19;
12.5%), sepsis (n ¼ 2; 1.3%), neurologic (n ¼ 2; 1.3%)
and respiratory (n ¼ 4; 2%) dysfunction (pneumonia and
adult respiratory distress syndrome), right heart failure ow-
ing to right coronary artery occlusion (n¼ 2; 1.3%), bleed-
ing (n ¼ 2; 1.3%), mesenteric ischemia (n ¼ 3; 2%), and
uncertain etiology (n ¼ 3; 2%). Eight patients died intrao-
peratively owing to cardiac failure and hemorrhage.
In the non-PVE group, univariate analysis of predictors
of mortality identified preoperative unstable status (OR,
8.5; 95% CI, 1.7–41.1; P ¼ .01), emergency indication
for operation (OR, 4.2; 95% CI, 1.1–15.6; P ¼ .02), con-
comitant procedures (mitral valve surgery: OR, 3.8; 95%
CI, 1.1–12.3; P ¼ .02; CABG: OR, 3.1; 95% CI, 1.2–7.7;
P ¼ .01), and NYHA class IV (OR, 2.2; 95% CI, 1.1–4.7;
P ¼ .01). Multivariate analysis identified only concomitant
procedures (CABG: OR, 8.1; 95% CI, 2.0–33.0; P<.01;
mitral valve surgery: OR, 4.8; 95% CI, 1.3–17.9;
P ¼ .02) as an independent predictor of mortality.
Patients without PVE died of low cardiac output (n ¼ 4;
3%), sepsis (n ¼ 2; 1.2%), neurologic (n ¼ 2; 1.2%) and
respiratory dysfunction (n ¼ 1; 0.6%), right heart failure
(n ¼ 2; 1.2%), mesenteric ischemia (n ¼ 1; 0.6%) and
uncertain etiology (n ¼ 1; 0.6%).
Analysis of Predictors of Long-Term Survival
Follow-up was 97.4% complete with a mean of 6.5 0.4
years (range, 0–12 years) and a total of 620.3 patient-years.
The 1, 3, 5, and 10-year survivals for patients with and with-
out PVE were 52%  4% versus 82%  3%, 43%  5%
versus 73%  4%, 37%  5% versus 63%  5%, and
31%  7% versus 56%  8% (log rank P < .001)
(Figure 1, A). For complicated and uncomplicated PVE,
the 1, 3, 5, and 10-year survivals were 44%  5% versus
64% 7%, 38% 5% versus 53% 8, 38% 5% ver-
sus 41%  9, and 0% versus 41%  9% (P ¼ .028)
(Figure 1, B). Survival was worse for patients with uncom-
plicated PVE than for the non-PVE group (P ¼ .02). There
was no significant difference in survival between early and
late endocarditis (P ¼ .68) or between Staph versus non-
Staph infection (P ¼ .8). Independent predictors of long-
term survival in patients with PVE were sepsis (OR, 3.1;
95% CI, 1.5–4.5; P<.01) and unstable preoperative status102 The Journal of Thoracic and Cardiovascular Surg(OR, 1.8; 95% CI, 1.2– 3.5; P ¼ .04), whereas in non-PVE
patients the predictor was NYHA class IV (OR, 2.5; 95%
CI, 2.8–7.4; P<.01).
Thirteen patients needed a second reoperation for PVE
(PVE group, n ¼ 10; non-PVE group, n ¼ 3). Seven of 10
patients with PVE who subsequently had recurrent PVE
had a root abscess at their first reoperation. Actuarial 5-
year freedom from endocarditis was 80%  0.3% (PVE)
versus 95%  0.6% (non-PVE) (log rank P ¼ .002)
(Figure 1, C).DISCUSSION
In one of the largest published series of patients with ac-
tive aortic PVE undergoing surgical intervention, this study
demonstrates high mortality (24.3%) and poor mid and
long-term survival (37% at 5 years, 31% at 10 years) de-
spite contemporary medical and surgical treatment, under-
lining the fact that treatment of this group of patients still
remains a therapeutic challenge. High-risk subgroups
were those with sepsis, poor left ventricular function, peri-
annular complications, and those requiring concomitant
CABG. In fact, those with uncomplicated PVE did not
have a significantly different mortality from those having
nonendocarditic reoperations. Endocarditis recurred in
one fifth of patients within 5 years. Reoperative AVR for
nonendocarditic causes was associated with lower mortality
(6.8%) and better long-term survival (63% at 5 years, 56%
at 10 years), representing the very different disease pro-
cesses, preoperative patient characteristics, and intraopera-
tive challenges of these patients.
The operative mortality for both PVE and non-PVE
reoperations observed in this study compares favorably
with contemporary data.5,6 Many studies report mortality
for reoperation for PVE ranging between 20% and 29%.7-9
The most comprehensive study to date concerning
PVE (The International Collaboration on Endocarditis–
Prospective Cohort Study) reported an in-hospital mortality
of 22.8% among 556 PVE patients.3 This study identified
older age, health care–associated infection, Staph aureus
infection, and complicated PVE as predictors of mortality,
confirming in a large number of patients the presence of
high-risk subgroups. Similarly, we identified the complica-
tions of sepsis and periannular abscess as predictors of
mortality.
The surgical treatment of root abscesses is a challenge, and
our study confirmed the association of periannular complica-
tionswith both increased earlymortality and Staphylococcus
infection. Aortic root abscesses occurred in 42%, which is
higher than the 19% to 29% previously reported.7,10 In our
data, 50% of patients with Staphylococcus infection and
32% with S aureus infection had a root abscess. Prior data
have demonstrated (1) higher mortality for patients with
periannular abscesses, (2) higher incidence of rootery c July 2011
FIGURE 1. A, Kaplan–Meier survival after reoperative aortic valve surgery for patients with and without PVE. B, Kaplan–Meier survival after reoperative
aortic valve surgery for patients with PVE stratified by complications. C, Freedom from endocarditis after redo aortic valve surgery for patients with and
without PVE. PVE, Prosthetic valve endocarditis.
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Staphylococcus infection (vs non-Staph), and (3) S aureus
infection to be an independent prognostic factor for
mortality in patients who have abscess formation.11,12
Sepsis was a predictor of both mortality and long-term
survival, which is concordant with data from DavierwalaThe Journal of Thoracic and Caand associates.5 Staphylococcus is the most frequent causa-
tive organism in early PVE, where it is considered a perio-
perative contaminant, has an incidence of 24% to 40%, and
has been shown to be a predictor of in-hospital mortality
and late death in some13 but not all studies.14 It is not pos-
sible to conclude from our data that high-risk subgroupsrdiovascular Surgery c Volume 142, Number 1 103
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Dsuch as this should be managed more aggressively or that
uncomplicated PVE can be managed with antibiotics alone
inasmuch as we do not have a medically treated PVE group
for comparison.
Additionally, poor left ventricular function and concom-
itant CABG were predictors of mortality. Increasing opera-
tive complexity by adding concomitant procedures has been
previously shown to increase risk,15 and our findings con-
cur. Kumar and associates16 found all other valvular proce-
dures performed simultaneously with reoperative aortic
valve surgery were univariate predictors of mortality,
whereas several studies have documented increased risk
with concomitant CABG, which is likely related to embolic
coronary occlusion.17
There was no effect of the previous type of prosthesis on
the early and long-term survival. However, data from Tang
and coworkers15 suggest that explanting mechanical valves
is associated with higher perioperative mortality than is ex-
planting bioprosthetic valves, likely because of different
modes of failure and presentation; the authors further sug-
gest that this should be considered when patient and sur-
geon are discussing valve type.15 Potter and associates6
also recommend the expanded use of bioprosthetic valves
but on the basis that the risk of reoperation is similar to
that for primary surgery. Potentially, our results have impli-
cations for the use of bioprosthetic valves among younger
patients needing a reoperation for PVE. In our series,
86% of patients with PVE had a biological valve substitute.
However, inasmuch as less than one third of patients sur-
vived 10 years, structural valve dysfunction is unlikely to
be an issue for most patients.
Patients with PVE were more likely to have had either
a xenograft or concomitant mitral valve surgery, and less
likely to have had a mechanical prosthesis, at the primary
operation than were patients without endocarditis. It is not
possible to conclude from this information that patients
having xenografts at the primary operation are more likely
to have PVE, or vice versa for mechanical valves; we do not
know the denominator of the total number of xenografts or
mechanical prostheses inserted because in many cases the
primary operation had been performed in other centers.
The long-term survival of patients with PVE is signifi-
cantly lower than that of patients with either native valve en-
docarditis or other modes of failure of prosthetic valves.
The 5-year survival in our study of PVE patients was only
37%  5% (non-PVE 63%  5%), which is similar to
30% 6% reported by Cortina and colleagues.18 However,
other studies have reported better 5-year survivals ranging
from 59% to 64%, which may be related to differences in
patient characteristics.19,20 Our 10-year survival of 31%
is similar to the 37.6% reported by the UK Heart Valve
Registry.21 The University of Toronto group reported
a 15-year survival of 25% 7%,22 and Stanford University
reported a 20-year survival of 16%  7%.23 Regardless, it104 The Journal of Thoracic and Cardiovascular Surgis clear that long-term survival is poor, underlining the high-
risk nature of these patients.
The freedom from recurrent endocarditis of 80% at 5
years in this study compares favorably with 60% reported
by Akowauh and coworkers.24 In a recent study, Alonso-
Valle and colleagues7 reported 91% freedom from recurrent
endocarditis at 32 months. However, d’Udeken and associ-
ates25 reported a 10-year rate of 79%  9%, with all pa-
tients in whom this late complication developed having
a paravalvular abscess at the time of the original operation.
In our study, 70% of patients with PVE in whom a recur-
rence developed had an abscess at their first reoperation.Study Limitations
Several limitations of our study have to be outlined. First,
it is retrospective and nonrandomized, but we believe that
this is a reasonable approach to assess predictors of outcome
in one of the largest series of surgically treated patients with
active aortic PVE and has long-term follow-up that was
97% complete. Second, such a long-term experience will
inevitably be biased by a learning curve, intersurgeon vari-
ability, and improvements in perioperative medical and
surgical management.
In conclusion, despite contemporary medical and surgi-
cal therapy, reoperative aortic valve surgery in the setting
of PVE is still associated with high early mortality and
poor long-term survival. High-risk subgroups are those
with sepsis, periannular complications, poor left ventricular
function, and those requiring concomitant CABG. Long-
term survival is worse in those with sepsis or instability
before the operation.References
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